264 related articles for article (PubMed ID: 27279909)
1. Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications.
Ju HQ; Lu YX; Chen DL; Tian T; Mo HY; Wei XL; Liao JW; Wang F; Zeng ZL; Pelicano H; Aguilar M; Jia WH; Xu RH
Theranostics; 2016; 6(8):1160-75. PubMed ID: 27279909
[TBL] [Abstract][Full Text] [Related]
2. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
3. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
4. [Redox regulation in cancer stem cells].
Saya H
Nihon Rinsho; 2015 May; 73(5):790-4. PubMed ID: 25985632
[TBL] [Abstract][Full Text] [Related]
5. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.
Thanee M; Loilome W; Techasen A; Sugihara E; Okazaki S; Abe S; Ueda S; Masuko T; Namwat N; Khuntikeo N; Titapun A; Pairojkul C; Saya H; Yongvanit P
Cancer Sci; 2016 Jul; 107(7):991-1000. PubMed ID: 27176078
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
Wang F; Yang Y
Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
[TBL] [Abstract][Full Text] [Related]
7. Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.
Isobe S; Kataoka M; Endo J; Moriyama H; Okazaki S; Tsuchihashi K; Katsumata Y; Yamamoto T; Shirakawa K; Yoshida N; Shimoda M; Chiba T; Masuko T; Hakamata Y; Kobayashi E; Saya H; Fukuda K; Sano M
Am J Respir Cell Mol Biol; 2019 Sep; 61(3):367-379. PubMed ID: 30897333
[TBL] [Abstract][Full Text] [Related]
8. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.
Ishimoto T; Nagano O; Yae T; Tamada M; Motohara T; Oshima H; Oshima M; Ikeda T; Asaba R; Yagi H; Masuko T; Shimizu T; Ishikawa T; Kai K; Takahashi E; Imamura Y; Baba Y; Ohmura M; Suematsu M; Baba H; Saya H
Cancer Cell; 2011 Mar; 19(3):387-400. PubMed ID: 21397861
[TBL] [Abstract][Full Text] [Related]
9. CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
Kawano Y; Iwama E; Tsuchihashi K; Shibahara D; Harada T; Tanaka K; Nagano O; Saya H; Nakanishi Y; Okamoto I
Lung Cancer; 2017 Nov; 113():72-78. PubMed ID: 29110853
[TBL] [Abstract][Full Text] [Related]
10. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
11. Redox regulation in stem-like cancer cells by CD44 variant isoforms.
Nagano O; Okazaki S; Saya H
Oncogene; 2013 Oct; 32(44):5191-8. PubMed ID: 23334333
[TBL] [Abstract][Full Text] [Related]
12. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
13. CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells.
Horibe S; Kawauchi S; Tanahashi T; Sasaki N; Mizuno S; Rikitake Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):426-432. PubMed ID: 30448176
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells.
Wang J; Luo B; Li X; Lu W; Yang J; Hu Y; Huang P; Wen S
Cell Death Dis; 2017 Jun; 8(6):e2887. PubMed ID: 28640251
[TBL] [Abstract][Full Text] [Related]
15. Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling.
Liao J; Liu PP; Hou G; Shao J; Yang J; Liu K; Lu W; Wen S; Hu Y; Huang P
Mol Cancer; 2017 Feb; 16(1):51. PubMed ID: 28245869
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
17. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death.
Banjac A; Perisic T; Sato H; Seiler A; Bannai S; Weiss N; Kölle P; Tschoep K; Issels RD; Daniel PT; Conrad M; Bornkamm GW
Oncogene; 2008 Mar; 27(11):1618-28. PubMed ID: 17828297
[TBL] [Abstract][Full Text] [Related]
18. Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
Linher-Melville K; Nashed MG; Ungard RG; Haftchenary S; Rosa DA; Gunning PT; Singh G
PLoS One; 2016; 11(8):e0161202. PubMed ID: 27513743
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
Toden S; Tran HM; Tovar-Camargo OA; Okugawa Y; Goel A
Oncotarget; 2016 Mar; 7(13):16158-71. PubMed ID: 26930714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
